Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282928068> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4282928068 endingPage "31S" @default.
- W4282928068 startingPage "31S" @default.
- W4282928068 abstract "INTRODUCTION: Safety data from two Phase 3 trials of linzagolix, a GnRH receptor antagonist, for the treatment of women with uterine fibroids (UFs) for 52 weeks were reviewed for treatment emergent adverse events (TEAEs) of depression and other mood disorders. We note that the incidence of TEAEs of depression and other mood disorders, previously reported up to 24 weeks, was low and revealed no consistent drug-related pattern. METHODS: PRIMROSE 1 and 2 are randomized, double-blind, placebo-controlled Phase 3 trials investigating the efficacy and safety of linzagolix 100 mg and 200 mg once daily, with and without hormonal add-back therapy (ABT) in women with UFs. After 24 weeks, the placebo group in PRIMROSE2 was switched to 200 mg+ABT. The incidence of depression and other mood disorder TEAEs from week 24 to week 52 was assessed using the Standardized MedDRA Query for Depression and suicide/self-injury and adding TEAEs of anxiety. RESULTS: Safety data from 336 and 421 patients, in PRIMROSE1 and PRIMROSE2, respectively, were collected from week 24 to week 52. Mood swings were reported for one (1.1%) subject in PRIMROSE2, and anxiety was reported in one (1.1%) subject in PRIMROSE1, both in the placebo/200 mg+ABT group. Depression was reported in one (1.1%) subject in PRIMROSE2 in the 200 mg/200 mg+ABT group. There were no reports of suicidal ideation, affect lability, or altered mood. CONCLUSION: The low incidence of depression and other mood disorder TEAEs was maintained up to 52 weeks of treatment with linzagolix. Linzagolix appears to be well tolerated in women with symptomatic UFs." @default.
- W4282928068 created "2022-06-16" @default.
- W4282928068 creator A5003343672 @default.
- W4282928068 creator A5003848425 @default.
- W4282928068 creator A5023340631 @default.
- W4282928068 creator A5035910379 @default.
- W4282928068 creator A5052083049 @default.
- W4282928068 creator A5067088712 @default.
- W4282928068 date "2022-05-01" @default.
- W4282928068 modified "2023-10-18" @default.
- W4282928068 title "Incidence of Mood Disorders in Women Treated With Linzagolix: 52-week Results From Two Phase 3 Trials [A106]" @default.
- W4282928068 doi "https://doi.org/10.1097/01.aog.0000826744.44400.f7" @default.
- W4282928068 hasPublicationYear "2022" @default.
- W4282928068 type Work @default.
- W4282928068 citedByCount "0" @default.
- W4282928068 crossrefType "journal-article" @default.
- W4282928068 hasAuthorship W4282928068A5003343672 @default.
- W4282928068 hasAuthorship W4282928068A5003848425 @default.
- W4282928068 hasAuthorship W4282928068A5023340631 @default.
- W4282928068 hasAuthorship W4282928068A5035910379 @default.
- W4282928068 hasAuthorship W4282928068A5052083049 @default.
- W4282928068 hasAuthorship W4282928068A5067088712 @default.
- W4282928068 hasConcept C118552586 @default.
- W4282928068 hasConcept C120665830 @default.
- W4282928068 hasConcept C121332964 @default.
- W4282928068 hasConcept C126322002 @default.
- W4282928068 hasConcept C139719470 @default.
- W4282928068 hasConcept C142724271 @default.
- W4282928068 hasConcept C162324750 @default.
- W4282928068 hasConcept C197934379 @default.
- W4282928068 hasConcept C199475168 @default.
- W4282928068 hasConcept C204787440 @default.
- W4282928068 hasConcept C27081682 @default.
- W4282928068 hasConcept C2776867660 @default.
- W4282928068 hasConcept C2777134132 @default.
- W4282928068 hasConcept C2780733359 @default.
- W4282928068 hasConcept C558461103 @default.
- W4282928068 hasConcept C57658597 @default.
- W4282928068 hasConcept C61511704 @default.
- W4282928068 hasConcept C71924100 @default.
- W4282928068 hasConceptScore W4282928068C118552586 @default.
- W4282928068 hasConceptScore W4282928068C120665830 @default.
- W4282928068 hasConceptScore W4282928068C121332964 @default.
- W4282928068 hasConceptScore W4282928068C126322002 @default.
- W4282928068 hasConceptScore W4282928068C139719470 @default.
- W4282928068 hasConceptScore W4282928068C142724271 @default.
- W4282928068 hasConceptScore W4282928068C162324750 @default.
- W4282928068 hasConceptScore W4282928068C197934379 @default.
- W4282928068 hasConceptScore W4282928068C199475168 @default.
- W4282928068 hasConceptScore W4282928068C204787440 @default.
- W4282928068 hasConceptScore W4282928068C27081682 @default.
- W4282928068 hasConceptScore W4282928068C2776867660 @default.
- W4282928068 hasConceptScore W4282928068C2777134132 @default.
- W4282928068 hasConceptScore W4282928068C2780733359 @default.
- W4282928068 hasConceptScore W4282928068C558461103 @default.
- W4282928068 hasConceptScore W4282928068C57658597 @default.
- W4282928068 hasConceptScore W4282928068C61511704 @default.
- W4282928068 hasConceptScore W4282928068C71924100 @default.
- W4282928068 hasIssue "1" @default.
- W4282928068 hasLocation W42829280681 @default.
- W4282928068 hasOpenAccess W4282928068 @default.
- W4282928068 hasPrimaryLocation W42829280681 @default.
- W4282928068 hasRelatedWork W1608467113 @default.
- W4282928068 hasRelatedWork W1981286639 @default.
- W4282928068 hasRelatedWork W2005633252 @default.
- W4282928068 hasRelatedWork W2393542146 @default.
- W4282928068 hasRelatedWork W2405043795 @default.
- W4282928068 hasRelatedWork W2990341048 @default.
- W4282928068 hasRelatedWork W3158250683 @default.
- W4282928068 hasRelatedWork W3164568171 @default.
- W4282928068 hasRelatedWork W3199018729 @default.
- W4282928068 hasRelatedWork W1480148196 @default.
- W4282928068 hasVolume "139" @default.
- W4282928068 isParatext "false" @default.
- W4282928068 isRetracted "false" @default.
- W4282928068 workType "article" @default.